Chris Ellis
Chief Operating Officer presso Vaccitech (UK) Ltd.
Patrimonio netto: 179 $ in data 31/03/2024
Profilo
Chris Ellis is currently the Chief Operating Officer at Vaccitech (UK) Ltd.
Prior to this, he worked as a Project Leader at Akamis Bio Ltd.
from 2013 to 2016.
He also held the position of Head-Clinical Operations at Barinthus Biotherapeutics Plc from 2016 to 2023.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 03/01/2023 | 75 ( 0.00% ) | 179 $ | 31/03/2024 |
Posizioni attive di Chris Ellis
| Società | Posizione | Inizio |
|---|---|---|
Vaccitech (UK) Ltd.
 Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | Chief Operating Officer | 01/08/2016 |
Precedenti posizioni note di Chris Ellis
| Società | Posizione | Fine |
|---|---|---|
| BARINTHUS BIOTHERAPEUTICS PLC | Chief Operating Officer | 31/10/2023 |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Corporate Officer/Principal | 01/08/2016 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Vaccitech (UK) Ltd.
Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | Commercial Services |
| Vaccitech Plc |
- Borsa valori
- Insiders
- Chris Ellis
